Business
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
Interactive Experience Designed to Showcase the 136,000sf cGMP Facility Located in Newark, CaliforniaCell Forge 1 is Operational in Preparation for the
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"Interactive Experience Designed to Showcase the 136,000sf cGMP Facility Located in Newark, CaliforniaCell Forge 1 is Operational in Preparation for the Company’s First Pivotal Trial with ALLO-501A for the Treatment of Relapsed/Refractory Non-Hodgkin LymphomaModular Facility Enables Flexibility and Control of Clinical Trial and Potential Commercial Production of Off-the-Shelf AlloCAR T™ ProductsEnvironmentally Sustainable and 100% Powered by Renewable Electricity SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the virtual unveiling of its manufacturing facility, Cell Forge 1 (“CF1”), located in Newark, California. The 136,000-square-foot facility is designed to support clinical trial and potential commercial production and worldwide distribution of allogeneic CAR T cell products for blood cancers and solid tumors. The virtual platform, designed to create an interactive and engaging CF1 virtual experience, includes welcome remarks from Allogene’s President, Chief Executive Officer and Co-Founder, David Chang, M.D., Ph.D., corporate and scientific videos, a 360° virtual tour of the facility, and a patient gallery. A Media Snippet accompanying this announcement is available by clicking on the image or link below: “Cell Forge 1 is a critical piece of our strategy for revolutionizing CAR T cancer therapy. As we prepare for our first AlloCAR T pivotal trial in mid-2022, we will draw on the capabilities of this state-of-the-art facility to meet product demand while maintaining important quality controls,” said Alison Moore, Ph.D., Chief Technical Officer of Allogene. “We believe this is an ideal time to bring the facility online. Cell Forge 1 is uniquely designed to grow with Allogene as we expand our pipeline, prepare for future regulatory filings, and scale up production for potential commercial distribution.” CF1 includes modular production suites, which are flexible and adaptable for growth. It also includes space for quality control testing, an environmental testing lab, and an advanced data system infrastructure, as well as administrative and warehouse space. Environmental sustainability was a key element of building design, including fea...